Weiguo Ye Sells Shares of Gyre Therapeutics, Inc.

On June 11, 2026, Weiguo Ye, the Chief Operating Officer of Gyre Therapeutics, Inc. (NasdaqCM:GYRE), sold 2,800 shares of the company at an average price of $6.17 per share. This transaction totaled $17,276 and was not part of a pre-planned trading program.

What Changed in Weiguo Ye's Gyre Therapeutics Position

Weiguo Ye reduced his holdings in Gyre Therapeutics by 2,800 shares in this transaction. The sale was executed at an average price of $6.17 per share, resulting in a total value of $17,276. This move comes amid regular trading activities by insiders at the company.

Other Institutional Activity in Gyre Therapeutics

Several institutional investors have been active in Gyre Therapeutics recently. Vanguard Capital Management LLC significantly increased its holdings by 984,204 shares, reaching a total of 984,204 shares valued at approximately $6.86 million. BlackRock, Inc. added 38,339 shares, bringing its total to 758,630 shares worth about $5.29 million. Geode Capital Management, LLC also expanded its position, adding 8,192 shares for a new total of 431,414 shares valued at $3.01 million. Meanwhile, State Street Corp increased its stake by 14,101 shares to 216,326 shares, valued at $1.51 million. In contrast, Charles Schwab Investment Management Inc trimmed its holdings by 3,920 shares, leaving it with 165,238 shares valued at roughly $1.15 million.

Gyre Therapeutics Stock Snapshot

Shares of Gyre Therapeutics (NasdaqCM:GYRE) recently traded around $5.86. The company has a market capitalization of approximately $575.4 million and a forward P/E ratio of 98.83. The stock's beta is high at 4.923, indicating significant volatility. Over the past 52 weeks, Gyre's stock has ranged from a low of $5.44 to a high of $9.42. The 50-day moving average is $6.96, while the 200-day moving average stands at $7.54. The company has a strong current ratio of 4.636 and a quick ratio of 3.679, with a debt-to-equity ratio of 0.601.

Recent Earnings

Gyre Therapeutics reported revenue of $117.05 million, reflecting modest growth of 2.1%. However, the company posted a net margin of -5.44% and a return on equity of -3.08%, indicating ongoing challenges in profitability. The next earnings release is scheduled for May 7, 2026.

Insider Buying and Selling at Gyre Therapeutics, Inc.

In addition to the recent sale, Weiguo Ye engaged in several transactions around the same period. On June 10, 2026, he sold another 6,418 shares at an average price of $6.21. These transactions were not conducted under a Rule 10b5-1 trading plan.

Analysts Set New Price Targets

Analysts have shown interest in Gyre Therapeutics with new ratings. On October 10, 2025, Jefferies initiated coverage with a buy rating and set a price target of $16. Similarly, HC Wainwright & Co. started coverage on August 26, 2025, with a buy rating and a target price of $18. The consensus among analysts is a strong buy, with a mean target price of $18.67 based on three analyst opinions.

About Gyre Therapeutics

Gyre Therapeutics, Inc. is a biotechnology company based in San Diego, California. It focuses on developing and commercializing small-molecule drugs aimed at treating inflammatory and fibrotic diseases. The company's flagship product, ETUARY, is approved for idiopathic pulmonary fibrosis and is in Phase 3 trials for other conditions. Gyre is also advancing other drug candidates targeting liver fibrosis and pulmonary diseases. Led by CEO Dr. Ying Luo, the company employs around 625 people.

Bottom Line

Weiguo Ye's recent sale of Gyre Therapeutics shares reflects ongoing insider trading activities within the company. Investors often scrutinize such transactions for insights into executive confidence. While Gyre's stock has shown volatility, analysts remain optimistic with strong buy ratings and high price targets. As always, it's important to remember that insider transactions and analyst ratings are just two pieces of the broader investment picture.